Yazdan Ghandi; Mahbod Soltani; Negar Poor Ahmadian; Samira Zakeri Shahvari; Mohammad Satarzadeh
Abstract
Background
Matrix metalloproteinases (MMPs) include a group of factors that are responsible for cell proliferation, apoptosis, and angiogenesis.This systematic study assessed previous ...
Read More
Background
Matrix metalloproteinases (MMPs) include a group of factors that are responsible for cell proliferation, apoptosis, and angiogenesis.This systematic study assessed previous studies to determine the therapeutic potential of the MMP in congenital heart disorders.
Method
This systematic review was written based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. All the articles from 2014-2024 were extracted from the Web of Science, PubMed and Scopus databases. We investigated the role of the MMP in the pathology of cardiovascular structural disorders and the therapeutic and diagnostic effects of MMP.
Results
15 were included in our study after checked by two authors. MMP-1, MMP-2, MMP-3, MMP-8, MMP-10, MMP-13, TIMP-1, and TIMP-4 were significantly elevated in patients with greater degrees of myocardial fibrosis and diastolic heart failure. MMP-2 and MMP-9 levels are significantly increased in hypertensive male BAV patients and are potentially associated with an aneurysmal cellular phenotype and MMP-1 may serve as a biomarker for ventricular remodeling in patients operated on for TOF.
Conclusion
The regulation of MMP levels during the fetal and postnatal periods can lead to the prevention and treatment of CHD. MMP/TIMP homeostasis is considered the key to CHD treatment and is even an important diagnostic tool.
